UNSPSC 51162006: Aminophylline/ephedrine/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162006 Aminophylline/ephedrine/phenobarbital is a Commodity code under which state and local governments procure pharmaceutical products and pharmacy services that diverge significantly from the code's nominal chemical name. Recent solicitations show state and local buyers actually seeking naloxone and drug deactivation systems for public health initiatives, on-site pharmacy services for employee health plans, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing. The issuing bodies include county health departments and government family health centers (Seminole County, Florida; Hall County, Georgia), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope spans procurement of naloxone units and safe drug deactivation systems for community health support, staffed on-site pharmacy operations at government clinics serving employee and retiree health plans, strategic initiatives to bypass traditional pharmacy benefit managers through direct manufacturer relationships, and large-volume generic pharmaceutical and OTC product supply agreements with specific NDC and SKU requirements, cGMP and Drug Supply Chain Security Act compliance, and tiered pricing models.

Recent activity concentrates in Florida, Georgia, Texas, and Minnesota, with MMCAP's multistate cooperative also serving Oregon and other participating jurisdictions. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to its community health building; Hall County's RFQ/P #47-010 (posted May 4, 2026, due June 4, 2026) for comprehensive on-site pharmacy services at its family health center clinic serving approximately 3,005 eligible individuals across multiple health plan types, with an 80/20 technical-to-cost evaluation weighting; and the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capability information on direct-to-manufacturer prescription programs outside traditional PBM channels. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) requires vendors to supply through three authorized wholesalers with products effective July 1, 2026, weighted 75 percent on price competitiveness and 25 percent on administrative and technical factors, with performance penalties ranging from $200 to $1,500 per violation.